解决基于干细胞疗法过早分娩的伦理挑战：ISSCR 2018 年年会重点会议报告。
Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report.
机构信息
Berman Bioethics Institute and Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
John van Geest Centre for Brain Repair and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
出版信息
Stem Cell Reports. 2018 Nov 13;11(5):1021-1025. doi: 10.1016/j.stemcr.2018.10.020.
Abstract
Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.
摘要
未经证实的基于干细胞的干预措施在临床上得到了广泛应用，但许多患者可能因接受这些干预而受到伤害，从而引发了复杂的伦理、经济和社会问题。监管机构、科学家、临床医生、专业协会和患者权益组织需要共同阐明与基于干细胞的治疗方法的适当开发和应用相关的期望。
相似文献
1
Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report.解决基于干细胞疗法过早分娩的伦理挑战：ISSCR 2018 年年会重点会议报告。
Stem Cell Reports. 2018 Nov 13;11(5):1021-1025. doi: 10.1016/j.stemcr.2018.10.020.
2
ISSCR guidelines for the transfer of human pluripotent stem cells and their direct derivatives into animal hosts.ISCR 人类多能干细胞及其直接衍生细胞向动物宿主转移的指导原则。
Stem Cell Reports. 2021 Jun 8;16(6):1409-1415. doi: 10.1016/j.stemcr.2021.05.005. Epub 2021 May 27.
3
Ethical and policy issues in the clinical translation of stem cells: report of a focus session at the ISSCR Tenth Annual Meeting.临床干细胞转化研究中的伦理和政策问题：ISSCR 第十届年会专题会议报告。
Cell Stem Cell. 2012 Dec 7;11(6):765-7. doi: 10.1016/j.stem.2012.11.004.
4
Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines.制定全球干细胞研究和临床转化标准：2016 年 ISSCR 指南。
Stem Cell Reports. 2016 Jun 14;6(6):787-797. doi: 10.1016/j.stemcr.2016.05.001. Epub 2016 May 12.
5
ISSCR's Guidelines for Stem Cell Research and Clinical Translation: Supporting development of safe and efficacious stem cell-based interventions.国际干细胞研究学会干细胞研究和临床转化指南：支持安全有效的基于干细胞的干预措施的发展。
Stem Cell Reports. 2021 Jun 8;16(6):1394-1397. doi: 10.1016/j.stemcr.2021.05.011. Epub 2021 May 27.
6
ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update.国际干细胞研究学会干细胞研究与临床转化指南：2021 年更新版。
Stem Cell Reports. 2021 Jun 8;16(6):1398-1408. doi: 10.1016/j.stemcr.2021.05.012. Epub 2021 May 27.
7
The role of the International Society for Stem Cell Research (ISSCR) guidelines in disease modeling.国际干细胞研究学会（ISSCR）指南在疾病建模中的作用。
Dis Model Mech. 2024 Jul 1;17(7). doi: 10.1242/dmm.050947. Epub 2024 Jul 8.
8
Do we still need human embryonic stem cells for stem cell-based therapies? Epistemic and ethical aspects.我们是否仍需要人类胚胎干细胞进行基于干细胞的治疗？认识论和伦理方面。
Stem Cell Rev Rep. 2011 Nov;7(4):761-74. doi: 10.1007/s12015-011-9257-3.
9
Ethical considerations in stem cell research on neurologic and orthopedic conditions.神经和骨科疾病干细胞研究中的伦理考量
PM R. 2015 Apr;7(4 Suppl):S66-S75. doi: 10.1016/j.pmrj.2014.10.016. Epub 2015 Jan 14.
10
On the streets of San Francisco: highlights from the ISSCR Annual Meeting 2010.旧金山街头：2010 年 ISSCR 年会亮点。
Cell Stem Cell. 2010 Oct 8;7(4):443-50. doi: 10.1016/j.stem.2010.09.002.
引用本文的文献
1
US state laws on medical freedom and investigational stem cell procedures: a call to focus on state-based legislation.美国关于医疗自由和研究用干细胞程序的州法律：呼吁关注基于州的立法。
Cytotherapy. 2024 Apr;26(4):404-409. doi: 10.1016/j.jcyt.2024.01.002. Epub 2024 Feb 3.
2
Unproven cell interventions in Poland and the exploitation of European Union law on advanced therapy medicinal products.波兰未经证实的细胞干预措施与对欧盟先进治疗药物产品法规的利用。
Stem Cell Reports. 2023 Aug 8;18(8):1610-1620. doi: 10.1016/j.stemcr.2023.05.017. Epub 2023 Jun 29.
3
An Infodemic of Misinformation on Stem Cell Therapy Among the Population of Saudi Arabia: A Cross-Sectional Study.沙特阿拉伯人群中干细胞治疗错误信息的信息疫情：一项横断面研究。
Front Med (Lausanne). 2022 Mar 2;9:789695. doi: 10.3389/fmed.2022.789695. eCollection 2022.
4
ISSCR's Guidelines for Stem Cell Research and Clinical Translation: Supporting development of safe and efficacious stem cell-based interventions.国际干细胞研究学会干细胞研究和临床转化指南：支持安全有效的基于干细胞的干预措施的发展。
Stem Cell Reports. 2021 Jun 8;16(6):1394-1397. doi: 10.1016/j.stemcr.2021.05.011. Epub 2021 May 27.
5
Regenerative Medicine of Epithelia: Lessons From the Past and Future Goals.上皮组织再生医学：过去的经验与未来的目标
Front Bioeng Biotechnol. 2021 Mar 25;9:652214. doi: 10.3389/fbioe.2021.652214. eCollection 2021.
6
Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson's Disease to the Clinic: The Investigator's Perspective.将治疗帕金森病的先进治疗药物（ATMPs）推向临床：研究者的视角。
J Parkinsons Dis. 2021;11(s2):S129-S134. doi: 10.3233/JPD-212563.
7
Identification of the risks in CAR T-cell therapy clinical trials in China: a Delphi study.中国嵌合抗原受体T细胞疗法临床试验风险识别：一项德尔菲研究
Ther Adv Med Oncol. 2020 Oct 17;12:1758835920966574. doi: 10.1177/1758835920966574. eCollection 2020.
8
Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.应对加拿大未经证实的干细胞干预措施的监管和政策工具：行动的必要性。
BMC Med Ethics. 2019 Aug 6;20(1):51. doi: 10.1186/s12910-019-0388-4.
本文引用的文献
1
A roundtable on responsible innovation with autologous stem cells in Australia, Japan and Singapore.澳大利亚、日本和新加坡的自体干细胞负责任创新圆桌会议。
Cytotherapy. 2018 Sep;20(9):1103-1109. doi: 10.1016/j.jcyt.2018.06.004. Epub 2018 Aug 19.
2
Conditional Approvals for Autologous Stem Cell-Based Interventions: .基于自体干细胞干预措施的有条件批准：
Perspect Biol Med. 2018;61(1):59-75. doi: 10.1353/pbm.2018.0027.
3
The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?首例人源干细胞临床试验面临的挑战：这对伦理学和机构审查委员会意味着什么？
Stem Cell Reports. 2018 May 8;10(5):1429-1431. doi: 10.1016/j.stemcr.2018.04.010.
4
Open for business: a comparative study of websites selling autologous stem cells in Australia and Japan.开业经营：澳大利亚和日本自体干细胞销售网站的比较研究
Regen Med. 2017 Oct;12(7):777-790. doi: 10.2217/rme-2017-0070. Epub 2017 Nov 10.
5
'No one here's helping me, what do you do?': addressing patient need for support and advice about stem cell treatments.“这里没人帮我，你们是做什么的？”：关注患者对干细胞治疗支持与建议的需求
Regen Med. 2017 Oct;12(7):791-801. doi: 10.2217/rme-2017-0056. Epub 2017 Nov 8.
6
ClinicalTrials.gov, stem cells and 'pay-to-participate' clinical studies.美国国立医学图书馆临床试验数据库、干细胞与“付费参与”临床研究。
Regen Med. 2017 Sep;12(6):705-719. doi: 10.2217/rme-2017-0015. Epub 2017 Jul 19.
7
Marketing of unproven stem cell-based interventions: A call to action.未经证实的基于干细胞的干预措施的营销：行动呼吁。
Sci Transl Med. 2017 Jul 5;9(397). doi: 10.1126/scitranslmed.aag0426.
8
Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.玻璃体内注射自体“干细胞”治疗年龄相关性黄斑变性后的视力丧失
N Engl J Med. 2017 Mar 16;376(11):1047-1053. doi: 10.1056/NEJMoa1609583.
9
Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.成人自体干细胞的伦理与监管挑战：国际法规的比较综述
J Bioeth Inq. 2017 Jun;14(2):261-273. doi: 10.1007/s11673-017-9776-y. Epub 2017 Feb 28.
10
Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.在美国销售干细胞：评估直接面向消费者的行业。
Cell Stem Cell. 2016 Aug 4;19(2):154-157. doi: 10.1016/j.stem.2016.06.007. Epub 2016 Jun 30.
Zotero 插件